Pages that link to "Q31502942"

The following pages link to The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity (Q31502942):

Displaying 42 items.

• Synthetic Strategies for 5- and 6-Membered Ring Azaheterocycles Facilitated by Iminyl Radicals (Q26746980) (← links)
• Camptothecins: a review of their chemotherapeutic potential (Q28203339) (← links)
• Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin. (Q32044363) (← links)
• Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. (Q33380081) (← links)
• A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies (Q33387815) (← links)
• Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents (Q33841304) (← links)
• Design and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents (Q34036266) (← links)
• Metabolic pathways of the camptothecin analog AR-67 (Q34715481) (← links)
• The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma. (Q34928276) (← links)
• Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs (Q35026064) (← links)
• Anti-proliferative and apoptosis-inducing effects of camptothecin-20(s)-O-(2-pyrazolyl-1)acetic ester in human breast tumor MCF-7 cells. (Q35152747) (← links)
• Camptothecins in clinical development (Q35688238) (← links)
• Camptothecin and its analogues: a review on their chemotherapeutic potential (Q36153120) (← links)
• Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins (Q36838603) (← links)
• The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro (Q36935258) (← links)
• Cyclization-activated prodrugs. (Q37027131) (← links)
• Factors Affecting the Stability of Drugs and Drug Metabolites in Biological Matrices (Q37810212) (← links)
• Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin (Q38637981) (← links)
• Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives. (Q38712547) (← links)
• Progress in the medicinal chemistry of silicon: C/Si exchange and beyond (Q38737295) (← links)
• DNA topoisomerase-targeting chemotherapeutics: what's new? (Q39320242) (← links)
• Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. (Q39508657) (← links)
• Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors (Q39564741) (← links)
• Synthesis and antitumor activity of 10-arylcamptothecin derivatives (Q39589644) (← links)
• Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development (Q40562765) (← links)
• Determination of intraliposomal pH and its effect on membrane partitioning and passive loading of a hydrophobic camptothecin, DB-67. (Q42103426) (← links)
• Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67. (Q43080807) (← links)
• The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. (Q43698671) (← links)
• Synthesis and evaluation of a novel E-ring modified alpha-hydroxy keto ether analogue of camptothecin (Q43819219) (← links)
• Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats (Q44076450) (← links)
• Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin (Q44144609) (← links)
• Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin (Q44593849) (← links)
• Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues (Q45349901) (← links)
• Stabilization of the Karenitecin® lactone by alpha-1 acid glycoprotein (Q46780138) (← links)
• Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? (Q47220295) (← links)
• Silicon-containing analogs of camptothecin as anticancer agents (Q48120322) (← links)
• Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. (Q51730628) (← links)
• A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. (Q54943623) (← links)
• 3D-QSAR study of 20 (S)-camptothecin analogs (Q56864508) (← links)
• Monitor: molecules and profiles (Q73670287) (← links)
• The Emerging Role of the SLCO1B3 Protein in Cancer Resistance (Q90303582) (← links)
• Synthesis and biological evaluation of 10-substituted camptothecin derivatives with improved water solubility and activity (Q102986615) (← links)